

# Topical Minoxidil Alone and with Topical Lanoprost in Localized Alopecia Areata Treatment: Comparative Study (2019-2020)

Assist Professor Dr. Ahmed Abdulhussein Kawen

M. B. Ch. B; F.I.C.M.S. Department of Dermatology, College of Medicine, University of Thi-Qar, Iraq

E-mail: [ahmedpath@yahoo.com](mailto:ahmedpath@yahoo.com)

Article History:

Submitted: 20.01.2020

Revised: 24.03.2020

Accepted: 09.04.2020

## ABSTRACT

**Rationale:** Therapeutic choicement for patients with alopecia was of limited success, no hundred percent cure rate, and no choice for absolute remission without recrudescence.

**Aim:** Comparison of topical Lanoprost & Minoxidil versus topical Minoxidil only in treatment of localized alopecia areata.

**Methodology:** Interventional-controlled single blinded study that was involving (95) alopecia areata patients. That extended from 1<sup>st</sup> day of February 2019 to last week January 2020 In Al-Hussain teaching hospitals in Thi-Qar and Al-Muthana governorates., the patients crossly matched well and divided according to lines of treatment into two groups. ethical consent had been taken after full details explanation of research items and purpose.

**Results:** Post interventional assessment of the response difference in terms significant statistical differences (p value=0.002, 0.0001) between the two groups. The SALT II when compared before and

after treatment was decreasing in both groups but to a significantly better extent in group II

**Conclusions:** The treatments with 5% minoxidil in a combination with 0.005% lanoprost or 5% minoxidil alone were found to be effective and a better result with minoxidil only. implemented combination in the managements of alopecia areata is of great benefit in reduction of size and duration of treatment.

**Keywords:** minoxidil, lanoprost, alopecia areata

## Correspondence:

Ahmed Abdulhussein Kawen

M.B.Ch.B; F.I.C.M.S Department of Dermatology, College of Medicine, University of Thi – Qar, Iraq

E-mail: [ahmedpath@yahoo.com](mailto:ahmedpath@yahoo.com)

DOI: [10.31838/srp.2020.4.24](https://doi.org/10.31838/srp.2020.4.24)

©Advanced Scientific Research. All rights reserved

## INTRODUCTION

Alopecia areata (AA) is defined as a complex of an autoimmune disorder that causes non-scarring loss of hair. It is presents as well circumscribed patches of hair loss (1) that either limited to one or more discrete area, on the scalp or body, or it may involve the whole scalp (alopecia totalis) or the entire body (alopecia universalis). (2,3) The disease had unpredictable behavior with either spontaneous regrowth in 80% of the patient during the beginning of the disease or a rapid recurrences at any period of its course. (3,4)

Worldwide hospital-based studies reported an incidence of alopecia areata to be between 0.57% and 3.8% (5), with lifetime incidence of around 2%. (6) it found in both gender with a slight female :male gender bias, this may be because of females are more concerned about hair loss and its treatment. (7) The disease occur at any age group with an incidence that increased in a linear rate. (1) it is usually diagnosed at 33 years of age. (1) females are mostly present in adolescence with either nail involvement or an autoimmune disorder while male patients may be more likely to be diagnosed in childhood. (3)

More than half of patients of both sex and all age groups had a risk factors for "poor health –related quality of life" which including female sex, age between 20-50 years, job change, family stress, hair loss more than 25% and light skin color. (8)

Several comorbid medical conditions were reported with alopecia areata, the incidence of atopy about (11%-38%) (9), thyroid disease such as "thyroid peroxidase antibodies" about ( 17.7%), especially in female patient with a female: male ratio of 6.7:1 and double that of the general population (10), recently, diabetes mellitus was reported in (11.1%) (9) recent study reported high level of c-peptide and insulin indicating increased insulin resistance in AA patients (11) and lastly alopecia areata associated with several other autoimmune disorders such as SLE, vitiligo,

inflammatory bowel disease, rheumatoid arthritis and psoriasis. (9)

Patient with alopecia areata often had a family history of the disease, and the studies reported that, the disease had multifactorial genetic predisposition through the association with a different type of genes, including cytokine, histocompatibility complex (MHC) genes, immune system regulating gene and several genes expressed in hair follicle. (12) Environmental factors, such as psychosocial stress, viral infections, trauma, also have been thought to be a possible cause for the development of the disease. (4)

It has been found that the therapeutic choices for patients with alopecia was limited success, no hundred percent cure rate, and no choice for absolute remission without recrudescence. (2,3,13). Therapeutic choices include systemic steroid (local & systemic); topical irritants such as anthralin; topical immunotherapy; topical minoxidil; and systemic immuno suppressants such as methotrexate and cyclosporine (13,14) therapeutic success was different relying on the period of treatment and duration of disease. Alopecia areata usually disfiguring disease, so family, social support psychological therapy is a substantial aspects of disease management.

Aim of the aim of this study was to Comparison of Topical Lanoprost & minoxidil vs Topical minoxidil only in Treatment of Localized Alopecia Areata.

## PATIENTS AND METHOD

In two dermatology outpatient departments, Al-Husseini Teaching Hospital in Al-Muthanna and Al-Husseini Teaching Hospital in Thi Qar, that extended from 1<sup>st</sup> day of February 2019 to last week January 2020 of we went on an interventional study that was controlled single blinded involving (95) AA patients. All of the patients were diagnosed to have AA on clinical and trichoscopic basis. The detailed history taking included age, sex, emotional stress, BCG vaccination, address, vitiligo, diabetes mellitus,

connective tissue disease, inflammatory bowel disease , myasthenia gravis, thyroid disease, and family history of alopecia areata. Each patient was examined to reveal the site of predilection whether in scalp, beard, eye brows, eye lashes , and moustache. Also we were looking for any related nail changes. We used the dermoscope to reveal the exclamation mark, yellow dots, black dots, broken hairs and other related trichoscopic findings. The exclusion criteria were:-

1. Ophiasis and sialopho.
2. Alopecia totalis and universalis.
3. Pregnancy.
4. Any previous treatment to the disease during the last 2 months.
5. Any suspected allergy or contraindication to topical minoxidil and lanoprost.

Data were described in terms of mean, range and standard deviation. The severity of the disease was assessed according to SALT II which is the Severity of Alopecia Tool. The percentage of surface area of each single patch of hair loss is estimated in relation to the total surface area of the scalp then we get the summation of surface area of loss as a percentage, if there is more than one patch.

The score is estimated at the first presentation then at the end of follow up. The duration of treatment was 4-10 weeks and the patients were examined and photos taken at the middle and the end of treatment and recorded as absent in case of (0-25%) , partial in case of (26-75%) and complete in case of (76-100%) hair regrowth . Data were analyzed statistically using Statistical Package for Social Sciences

(SPSS) to attain the significance of results in terms of p value less than 0.05.

Patients were divided into two groups, group 1 got a solution prepared by mixing 60ml of 5% minoxidil solution and 2.5 ml of 0.005% lanoprost solution, and group 2 got 5% minoxidil solution only. Dose of preparation was in both groups was 1 ml to the affected patches twice daily regardless of the affected area.

## RESULTS

In addition to the random allocation we further excluded, from a statistical point of view, the bias between the two groups regarding age, gender, and duration of illness. Comparing all these parameters is shown in table (1). We extracted the p value of age matching which was not significant. Also the gender can interfere with the prognosis and outcome of treatment so the gender matching done and revealed a non-significant P value. Matching SALT II before treatment in both groups, to exclude bias, done also and the P value again was not significant as seen in table (2), so is the score after treatment.

Then after intervention we assessed the difference of response in terms of p value between the two groups as shown in table (3). The SALT II when compared before and after treatment was decreasing in both groups but to a significantly better extent in group II as shown in table (3). Some patients in both groups developed mild pruritic erythema which did not interfere with compliance. No systemic adverse effects reported. No physical changes noticed to therapeutic solutions during or after use.

Table 1: Demography of studied group

Groups Demographic data	Group I (N=50)	Group II (N= 45)	P. value
Age / year			
Range	4 – 45	4 - 45	0.998
Mean ± SD	24.57 ± 12.73	24.68 ± 13.25	
Duration \ months			
Range	1 – 13	1 - 13	0.876
Mean ± SD	3.06 ± 3.15	3.14 ± 3.31	
Gender			
Male (%)	21 (42%)	19 (42.22%)	0.983
Female (%)	29 (58%)	26 (57.78%)	
Total	50 (100%)	45 (100%)	

**P.value ≤ 0.05 Significant**

Table 2: Statistical difference of studied group (avoiding selection bias)

Groups	Group I (N=50)	Group II (N= 45)	P. value
Demographic data			
SALT before therapy			
Range	1 – 12	1 - 12	0.99
Mean ± SD	3.59 ± 2.57	3.59 ± 2.77	
SALT after therapy			
Range	0 – 12	0 - 12	0.191
Mean ± SD	2.88 ± 3.27	2.14 ± 1.90	

**P.value ≤ 0.05 Significant**

Table 3: SALT II comparison of pre and post treatment of the 2 groups

Group	Range SALT	Mean ± SD	P. value
Group I (N=50)			
Before therapy	1 – 12	3.59 ± 2.57	0.02
After therapy	0 – 12	2.87 ± 3.27	
Group II (N=45)			
Before therapy	1 – 12	3.59 ± 2.77	0.0001
After therapy	0 – 12	2.13 ± 1.89	

**P.value ≤ 0.05 Significant**

## DISCUSSION

Minoxidil is used in the treatment of systemic hypertension as a vasodilating drug and also used for the treatment of alopecia as a topical agent (15) while Latanoprost is indicated in the treatment of ocular hypertension and open angle glaucoma, its analogous to prostaglandin F<sub>2</sub>, this drug reported in the treatment of alopecia due to its side effects noticed in the ocular region, including hypertrichosis, increased thickening and lengthening of eye lash (16,17). minoxidil and latanoprost acts by mechanism which not fully understood. Minoxidil will stimulate hair follicle, especially those dormant, and prolonging the anagen phase (15) while latanoprost acts by stimulating the anagen phase, and increasing the conversion of vellus hair into terminal hair.

Although many therapeutic choices for patients with alopecia areata, but no therapy was effective, without side effects and cosmetically acceptable. So this study aimed to evaluate the effectiveness of minoxidil used isolatedly or in combination with latanoprost in the treatment of alopecia areata.

95 participants included in the study, all of them finished by 4-10 weeks. Group 1 (50) participants treated topically by latanoprost & minoxidil. Group 2 (45) participants treated by minoxidil only.

As comparing to other treatment modality, it seems to be they are easier for use with relatively less side effects. The study reported some patients in both groups developed mild pruritic erythema which did not interfere with compliance. No systemic adverse effects reported. No physical changes noticed to therapeutic solutions during or after use.

A comparison of the photos taken at the middle and at the end of the treatment was done.

By observing the results obtained before & after treatment, there was significant association between SALT and treatment in both groups, these results in accordance with findings reported by Bloch *et al.* (18) who concluded that, the treatments with 5% minoxidil alone or in combination with 0.005% latanoprost was effective in alopecia areata.

Regarding the minoxidil, previous Fenton study reported a response with four to six weeks and with less side effects. (19) The mechanism of hair growth stimulated by minoxidil like diazoxide (20) Although these drugs are chemically different but they act on blood vessel smooth muscle cells to prevent calcium uptake (21) making them a good vasodilator especially on the arteriole (22) that lead to decreasing heart afterload leading to increased blood flow. A study by Burton *et al.* proposed that good skin blood flow is accountable for hair growth (20) Humphrey proposed high skin blood flow with using of minoxidil. (23)

Topical application of glyceryl trinitrate (act on the vein rather than arteriole) didn't induce hair growth, proposing that, a dilatation of arteriolar blood vessels instead of venular are need for promotion of hair growth.(24) The mechanism of hair growth by minoxidil not related to hormonal androgenic stimulation that's approved by normal blood testosterone level & normal excreted urinary level of steroid (25,26)

Varothai approved that topical application of minoxidil will induce hair growth for both male and female with alopecia areata(27,28). Goren noticed that 40% of male patient with alopecia areata develop hair growth with 3-6 month of topical minoxidil (29). Virginia demonstrated a dose response relationship when treated two group of patient one with 1% minoxidil and other group with 5% minoxidil the response in the first group was 38% versus 81% in the second group.(30)

Although the action of lantoprost is not clearly obvious, but an interventional study reported that, it exerts its effects through prostaglandin analogues. So the direct use of these analogues may be more effective with prolong effects and abolish the pathomechanism of AA and therefore a competence drug for alopecia areata.(31,32)

Coronel noticed that, there was a moderate to total response in 45% of the patients after topical application of lantoprost for eye lash.(31) El-Ashrawy reported that, the addition of lantoprost to the topical betamethasone will increase the efficacy of betamethasone.(32).

This study approved more response with topical minoxidil only than minoxidil & lantoprost in a combination this agreed with Gita study who reported that lantoprost has no efficacy in the treatment of alopecia areata.(33)

Conclusions: The treatments with 5% minoxidil in a combination with 0.005% lantoprost or 5% minoxidil alone were found to be effective and a better result with minoxidil only.

## RECOMMENDATION

there is a need for further study to include a wide population to compare with these results and implemented in the managements of alopecia areata.

## REFERENCES

1. Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester epidemiology project, 1990-2009. *J Invest Dermatol.* 2014; 134:1141–2. [PMC free article] [PubMed] [Google Scholar]
2. Hordinsky MK. Overview of alopecia areata. *J Invest Dermatol Symp Proc.* 2013;16(1):S13–S15. [PubMed] [Google Scholar]
3. MacLean KJ, Tidman MJ. Alopecia areata: more than skin deep. *Practitioner.* 2013;257(1764):29–32. [PubMed] [Google Scholar]
4. Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. *Autoimmun Rev.* 2015;14(2):81–89. [PubMed] [Google Scholar]
5. Guzmán-Sánchez DA, Villanueva-Quintero GD, Alfaro Alfaro N, McMichael A. A clinical study of

- alopecia areata in Mexico. *Int J Dermatol.* 2007;46(12):1308–1310. [PubMed] [Google Scholar]
6. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: A systematic review. *Clin Cosmet Investig Dermatol.* 2015; 8:397–403. [PMC free article] [PubMed] [Google Scholar]
7. Lundin M, Chawa S, Sachdev A, Bhanusali D, Seiffert-Sinha K, Sinha AA, et al. Gender differences in alopecia areata. *J Drugs Dermatol.* 2014; 13:409–13. [PubMed] [Google Scholar] comprehensive review.
8. Shi Q, Duvic M, Osei JS, et al. Health-Related Quality of Life (HRQoL) in alopecia areata patients– a secondary analysis of the National Alopecia Areata Registry Data. *J Invest Dermatol Symp Proc.* 2013;16(1):S49–S50. [PubMed] [Google Scholar]
9. Huang KP, Mullangi S, Guo Y, Qureshi AA. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. *JAMA Dermatol.* 2013;149(7):789–794. [PubMed] [Google Scholar]
10. Baars MP, Greebe RJ, Pop VJ. High prevalence of thyroid peroxidase antibodies in patients with alopecia areata. *J Eur Acad Dermatol Venereol.* 2013;27(1):e137–e139. [PubMed] [Google Scholar]
11. Karadag AS, Ertugrul DT, Bilgili SG, Takci Z, Tatal E, Yilmaz H. Insulin resistance is increased in alopecia areata patients. *Cutan Ocul Toxicol.* 2013;32(2):102–106. [PubMed] [Google Scholar]
12. Petukhova L, Duvic M, Hordinsky M et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. *Nature* 2010; 466:113–17.
13. Shapiro J. Current treatment of alopecia areata. *Investig Dermatol Symp Proc.* 2013;16(1):S42–S44. [PubMed] [Google Scholar]
14. Karimkhani C, Boyers LN, Prescott L, et al. Global burden of skin disease as reflected in Cochrane Database of Systematic Reviews. *JAMA Dermatol.* 2014;150(9):945–951. [PubMed] [Google Scholar]
15. Pires FE, Fonseca MB, Ramos-e-Silva M. Minoxidil in alopecia areata. *Folha Médica* 1994;108(4):113–17.
16. Blume-Peytavi U, Lönnfors S, Hillmann K, Bartels NG. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by lantoprost 0,1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. *J Am Acad Dermatol.* 2012;66(5):794–800.
17. Sasaki S, Hozumi Y, Kondo S. Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model. *Exp Dermatol.* 2005;14(5):323–8.
18. Bloch LD, Escudeiro CC, Sarruf FD, Valente NYS. Lantoprost and minoxidil: Comparative double-blind, placebo-controlled study for the treatment of hair loss. DOI: <http://dx.doi.org/10.5935/scd1984-8773.20181011015>

19. FENTON AD, WILKINSON JD. Topical minoxidil in the treatment of alopecia areata. BRITISH MEDICAL JOURNAL .1983; 287 :1015-1017.
20. Burton JL, Schutt WH, Caldwell IW. Hypertrichosis due to diazoxide.Br Jt Dermatol .1975;93:707-1 1.
21. Chidley CA, Gottlieb TB. The pharmacologic basis of antihypertensive therapy: the role of vasodilator drugs. Prog Cardiovasc Dis .1974;27:99-113.
22. Lowenthal DT , Affrime MB .Pharmacology and pharmacokinetics of minoxidil. J Cardiovasc Pharmacol .1980;suppl 2:93-106.
23. Humphery SJ, Wilson E , Zins GR Whole body tissue blood flow in conscious dogs treated with minoxidil. [Abstract.] Fed Proc 1974 ;33 :583
24. Fenton DA, Wilkinson JD. Alopecia areata treated with topical minoxidil. J R Soc Med .1982;75:963-5
25. Earhart RN, Ball J, Nuss DD, et al. Minoxidil induced hypertrichosis: treatment with calcium thioglycolate depilatory. South Med J .1977; 70:442-5.
26. Ryan JR, Jain AK, McMahon FG. Minoxidil treatment of severe hypertension. Current Therapeutic Research 1975 ;17 :55-6.
27. Varothai S,Bergfeld WF . Androgenetic alopecia: an evidence-based treatment update. *American Journal of Clinical Dermatology*.2014; 15 (3): 217–30. doi:10.1007/s40257-014-0077-5 (https://doi.org/10.1007/s40257-014-0077-5). PMID 24848508 (<https://pubmed.ncbi.nlm.nih.gov/24848508>).
28. Van Zuuren EJ,Fedorowicz Z, Schoones J . Interventions for female pattern hair loss.*TheCochrane Database of Systematic Reviews* .2016;(5): CD007628 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457957).
29. Shankarappa, R.K., Agrawal, N., Patra, S., Karur, S., Nanjappa, M.C. An unusual percutaneous transmitral commissurotomy: A collection of four rare occurrences! (2013) Journal of Cardiovascular Disease Research, 4 (3), pp. 191-194. DOI: 10.1016/j.jcdr.2013.08.003
30. Goren A, Shapiro J, Roberts J ,et al . Clinical utility and validity of minoxidil response testing in androgenetic alopecia. *DermatolTher*.2015 ; 28 (1): 13–6.
31. Virginia C, Fiedle W. Topical minoxidil solution (1%and5%)in the treatment of alopecia areata. Journal of the American Academy of Dermatology.1987;16(3):745-748.
32. Coronel Pérez IM , Rodríguez Rey EM, Camacho Martínez FM:Latanoprost in the treatment of eyelash alopecia in alopecia areatauniversalis.J EurAcadDermatolVenereol. 2010 Apr;24(4):481-5. doi: 10.1111/j.1468-3083.2009.03543.x. Epub 2009 Dec 17.
33. El-Ashmawy AA,IH El-Maadawy,El-Maghraby GM.Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment alopecia areata. Journal Of dermatological treatment. 2017. https://doi.org/10.1080/09546634.2017.1330527
34. Faghihi G, Andalib F, Asilian A. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. Eur J Dermatol 2009; 19 (6): 586-7.